Merit Medical Acquires Solo Pace, Inc., Expanding Its Cardiac Therapies Platform with Innovative TAVR Pacing Technology
Merit Medical acquired all remaining equity of Solo Pace, Inc. for approximately $45 million, closing on October 13, 2026, after previously holding ~18% and serving as exclusive distributor. The deal adds SOLO PACE CONTROL and SOLO PACE FUSION temporary pacing systems purpose-built for TAVR and other transcatheter heart valve procedures, expanding Merit's Cardiac Therapies and structural heart portfolio in a market with more than 100,000 annual U.S. TAVR procedures.
Key figures
- Deal Value Usd
- 45000000
- 2027 impact
- slightly accretive to non-GAAP net income/EPS; slightly dilutive to GAAP
- Prior ownership
- ~18% (acquired for $5M total between Jan 2023 and Dec 2025)
- Transaction costs excluded
- $3.2 million non-cash and non-recurring
- Interest income impact 2027
- $1.5 million lower
- Tavr procedures us annually
- more than 100,000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.